Zobrazeno 1 - 5
of 5
pro vyhledávání: '"José María Castellano Vázquez"'
Autor:
Konstantinos Tsioufis, Franco Mondello Malvestiti, José María Castellano Vázquez, Joris van Vugt, Georgia Sykara
Publikováno v:
Cardiology and Therapy
Atorvastatin, which has been approved by regulatory agencies for primary- and secondary-prevention patients with dyslipidemia, has historically been the most commonly prescribed statin and is now widely available in generic formulations. Despite wide
Publikováno v:
Revista Española de Cardiología (English Edition). 73:194-196
Autor:
Jose F. Varona, Leticia Fernández-Friera, Isabel Sánchez-Vera, Beatriz López-Melgar, Fernando Vidal-Vanaclocha, Roberto Ortiz-Regalón, José María Castellano Vázquez, Cira García-Durango, Jorge Solis
Publikováno v:
Archives of Medical Research. 50:20-28
Metabolic syndrome (MetS) is a heterogeneous clinical entity associated with insulin resistance, low-grade proinflammatory balance and impaired endothelial function, accelerating atherosclerosis. Atherosclerotic lesions worsen with age, smoking and c
Publikováno v:
Revista Española de Cardiología. 70:532-534
Autor:
Luciano Consuegra-Sánchez, José María Castellano Vázquez, Luis Lozano Mera, Francisco J. Félix-Redondo, Fernando Giménez Sáez, Francisco Javier Garcipérez de Vargas, Daniel Fernández-Bergés
Publikováno v:
Open Heart
Repisalud
Instituto de Salud Carlos III (ISCIII)
Repisalud
Instituto de Salud Carlos III (ISCIII)
OBJECTIVES: To determine the degree of risk factor control, the clinical symptoms and the therapeutic management of patients with a history of previous myocardial infarction. METHODS: Cross-sectional study at 6 years of a first episode of acute myoca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ec7f52c776d0cf6daee5e964b5c067
https://hdl.handle.net/20.500.12105/7215
https://hdl.handle.net/20.500.12105/7215